Stoke Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

Stoke Therapeutics

01/08/2025 14:14

Stoke Therapeutics Inc STOK.OQ STOK.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2025

The Bedford Massachusetts-based  company is expected to report a 84.5% increase in revenue to $8.911 million from $4.83 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Stoke Therapeutics Inc is for a loss of 51 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Stoke Therapeutics Inc is $22.00, about 41.6% above its last closing price of $12.85

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.41
-0.42
1.98
Beat
567.8
Dec. 31 2025
-0.52
-0.53
-0.18
Beat
65.9
Sep. 30 2024
-0.53
-0.53
-0.47
Beat
11.8​
Jun. 30 2024
-0.56
-0.56
-0.46
Beat
17.9
​​Mar. 31 2024
-0.61
-0.61
-0.57
Beat
6.6
Dec. 31 2023
-0.48
-0.63
-0.60
Beat
4.8​
Sep. 30 2023
-0.64
-0.63
-0.55
Beat
12.4
Jun. 30 2023
-0.62
-0.64
-0.69
Missed
-8.4

This summary was machine generated August 1 at 13:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)